For the past few years, we were in a climate in biopharma where breadth of a platform seemed paramount. The pendulum is now swinging the other way and investors are looking for depth as well. How much data has been generated? Do you have a clear path to clinically and...1/5
...commercially relevant programs (not just a good indication in which to test the platform)? What is your differentiation relative to others in the space – both in terms of similar platforms, and in terms of different modalities being tested in your lead indication? 2/5
...It’s still very valuable to have a platform on which many drug programs can be created; but given the rapid proliferation of platform companies, crowding around the most promising targets and highest-unmet need indications, challenges with some new modalities in terms of...3/5
...clinical data, regulatory progress, and commercial uptake, and of course, the public market performance, investors now ask for a bit more. So if you’re a company with an exciting platform, and you’ve already raised significant capital and you’re out raising more, be sure...4/5
...to balance all the discussion of the great progress on your platform with detail on how and when you’re going to put programs into the clinic – and why they’ll matter. Innovative science only matters to patients if it can eventually produce drugs! 5/5
@SaraNayeem Really insightful thread! So important to consider
@SaraNayeem @tresselapp save thread